Causes and risks of hyperlipidemia during dialysis and following kidney transplant;Cause e rischi dell'iperlipidemia durante trattamento dialitico e dopo trapianto renale

Recenti Progressi in Medicina

Volumn 89, Issue 11, 1998, Pages 590-597

  Verzola, Adriano ^a   Perini, Leonella ^a   Gatto, Stefano ^a   Gilli, Paolo ^a   Bedani, Pier Luigi ^a  

^a SANT ANNA HOSPITAL   (Italy)

Author keywords

Chronic renal insufficiency; Dialysis; Hyperlipidemia; Kidney transplant

Indexed keywords

CHRONIC KIDNEY FAILURE; HUMAN; HYPERLIPIDEMIA; KIDNEY TRANSPLANTATION; METABOLISM; RENAL REPLACEMENT THERAPY; REVIEW; RISK; RISK FACTOR;

HUMANS; HYPERLIPIDEMIAS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; RENAL DIALYSIS; RISK; RISK FACTORS;

EID: 0032201086     PISSN: 00341193     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. Oda H, Keane WF. Lipid abnormalities in end stage renal disease. Nephrol Dial Transplant 1998;13(suppl 1): 45-9.
2. Dimèny E, Fellström B. Metabolic abnormalities in renal transplant recipients. Risck factors and predictors of chronic graft disfunction?. Nephrol Dial Tranplant 1997 (Editorial Comments); 12: 21-4.
3. Fellin R, Vigna GB, Zuliani G. Malattie metaboliche in: GC Agnoli et al., eds. Fisiopatologia. Bologna: Clueb 1993; 273-368.
4. Scanu AM. Physiopathology of plasma lipoprotein metabolism. Kidney International 1991; 39 (suppl 31): S-3 - S-7.
5. Mbewu AD, Durrington PN. Lipoprotein (a). Structure, properties and possible involvement in thrombogenesis in atherogenesis. Atherosclerosis 1990; 85: 1-14.
6. Hael JR, Kane JP. Structure and metabolism of plasma lipoproteins. In: Scrivner CR, Beaudett AL, Sly W, Valle D, eds. The Metabolic basis of inherited disease. New York: McGraw Hill 1989; 44A: 1129-38.
7. Attman PO, Alaupovic P. Lipid abnormalities in chronic renal insufficiency. Kidney International 1991; 39 (suppl 31): S-16 - S-23.
8. Chan MK, Varghese Z, Moorhead JF. Lipid abnormalities in uremia, dialysis and transplantation. Kidney International 1981; 19: 625-37.
9. Cappelli P, Di Liberato L, Sammartino F, et al. Ruolo dei lipidi nella progressione dell'insufficienza renale cronica. Giornale Italiano di Nefrologia 1995; 12: 81-7.
10. Cappelli P, Di Liberato L, Albertazzi A. Terapie antidislipidemiche nelle nefropatie. Giornale Italiano di Nefrologia 1996; 13: 69-78.
11. Kaysen GA. Hyperlipidemia of the nephrotic syndrome. 1991; 39 (suppl 31): S-8 - S-15.
12. Ricardo DS, van Goor H, Diamond JR. Hypercholesterolemia and progressive kidney disease: the role of macrophages and macrophages-derived products. In: Keane WF, Horl WH, Kasiske BL, eds. Lipids and the kidney. Contrib Nephrol 1997; 120: 197-209.
13. Rubies-Prat J, Espinel E, Joven J, Ras MR, Pira L. High density lipoprotein cholesterol sub fractions in chronic uremia. Am J Kidney Dis 1987; 9: 60-5.
14. Guamieri GF, Moracchiello M, Campanacci L, et al. Lecithin cholesterol acyl transferase (LCAT) activity in chronic uremia. Kidney Int 1978; 13 (suppl 8): S-26-30.
15. Neary RH, Gowland E. The effect of renal failure and haemodialysis on the concentration of free apolipoprotein A-I in serum and in the implications for the catabolism of high density lipoproteins. Clin Chim Acta 1988;171: 239- 46.
16. Kasiske BL, Keane WF. Causes, Consequences and treatment of hyperlipidemia in patients with renal disease. In: Andreucci VE, Fine LG eds. International Year Book of Nephrology. Boston: Kluwer Academic 1991: 179- 96.
17. Havel RJ, Hamilton RL. Hepatocytic lipoprotein Hepatology 1988; 8: 1689-1704.
18. Shoji T, Nishzawa Y, Nishitani H, Yamakawa M, Morii H. Impaired metabolism of high density lipoprotein in uremic patients. Kidney Int 1992; 41: 1653-1661.
19. Sakurai T, Oka T, Hasegawa H, et al. Comparison of lipids apoproteins and associated enzyme activities between diabetic and nondiabetic end stage renal disease. Nephron 1992; 61: 409-14.
20. Dahlen GH, Guyton JR, Attar M, Farmer JA, Kautz JA, Gotto AM. Association of levels of lipoprotein Lp (a), plasma lipids and other lipoprotein wiLh coronary disease documented by angiograghy. Circulation 1986; 74: 758-765.
21. Sandkamp H, Funke H, Shulte H, Cohler E, Assmann G. Lipoprotein (a) is an independent risk factor for myocardial infarction at young age. Clin Chem 1990; 36: 20-23.
22. Segarra A, Chacon P, Martin M et al. Serum lipoprotein (a) levels in patients with chronic renal failure. Evolution after renal transplantation and relationship with other parameters of lipoprotein metabolism: a prospective study. Nephron 1995; 69: 9-13.
23. Cocchi R, Viglino G, Cancarini G et al. Prevalence of hyperlipidemia in a cohort of CAPD patients. Miner Electrolyte Metab 1996; 22: 22- 5.
24. Chan MK, Varghese Z, Persaud JW, Baillod RA, Moorhead JF. Hyperlipidemia in patients on maintenance hemo and peritoneal dialysis: the relative pathogenetic roles of triglyceride production and triglyceride removal. Clin Nephrol 1982; 17: 183-90.
25. Breckenridge WC, Roncari DAK, Khanna R, Oreopoulos DG. The influence of continuous ambulatory peritoneal dialysis on plasma lipoproteins. Atherosclerosis 1982; 45: 249-258.
26. Attman PO, Samuelsson O, Alaupovic P. Lipoprotein metabolism and renal failure. Am J Kidney Dis 1993; 21: 573-92.
27. Chan MK, Ramdial L, Varghese Z et al.Plasma lecithin-cholesterol acyltransferase activities in uraemic patients. Clin Chim Acta 1982; 119: 65-72.
28. Steinmetz A, Barbaras R, Ghalim N et al. Human apolipoprotein A-IV binds to apolipoprotein A-I/AII receptor sites and promotes cholesterol efflux from adipose cells. J Biol Chem 1990; 265: 7859-63.
29. Steinmetz A, Utermann G. Activation of lecithin cholesterol acyltransferase by human apolipoprotein A-IV. Biol Chem 1985; 260: 2258-64.
30. Morton RE, Zilversmit DB. Purification and characterization of lipid transfert protein (s) from human lipoprotein-deficient plasma. J Lipid Res 1982; 23: 1058-67.
31. Asayama K, Hayashibe H, Mishiku Y et al. Increased activity of plasma cholesterol ester transfer protein in children with end stage renal disease receving continuous ambulatory peritoneal dialysis. Nephron 1996; 72: 231-6.
32. Chatzidimitriou C, Pliakogiannis T, Evangeliou A et al. Evaluation of carnitine levels according to the peritoneal equilibration test in patients on continuous ambulatory peritoneal dialysis. Perit Dial Int 1993; 13 (suppl 2): s444-47.
33. Diamond JR. Analogous pathobiologic mechanisms in glomerulosclerosis and atherosclerosis. Kidney Int 1991; 39 (suppl 31): S29-34.
34. Isoniemi H. Hyperlipidemia after renal transplantation. Facts and potential implications. Nephrol Dial Transplant 1995. Editorial Comments: 457-9.
35. Maggi E, Bellazzi R, Falaschi F et al. Enhanced LDL oxidation in uremic patients: an additional mechanism for accellerated atherosclerosis? Kidney Int 1994; 45: 876- 83.
36. Ghanem H, van der Dorpel MA, Weimar W, et al. Increased low density lipoprotein oxidation in stable kidney transplant recipients. Kidney Int 1996; 49: 488-93.
37. Raine AEG. Cardiovascular complication after renal transplantation. In: Morris PJ, ed. Kidney transplantation. Principles and practice. 4th edition. Philadelphia: Saunders 1994; 339.
38. Massy ZA, Guijarro C, Wiederkehr MR, Ma JZ, Kasiske BL. Chronic renal allograft rejection. Immunologic and nonimmunologic risk factors. Kidney Int 1996; 49: 518-24.
39. Dreuke TB, Abdulmassich Z, Lacour B, Bader C, Chevalier A, Kreis H. Atherosclerosis and lipid disorders after renal transplantation. Kidney Int 1991; 39 (suppl 31): S-24-28.
40. Kasiske BL, Umen AJ. Persistent hyperlipidemia in renal transplant patients. Medicine 1987; 66: 309-16.
41. Massy ZA, Kasiske BL. Post-transplant hyperlipidemia: mechanism and management. J Am Soc Nephrol 1996; 7: 971-77.
42. Vathsala A, Weinberg RB, Schoenberg L, et al. Lipid abnormalities in cyclosporine-prednisone treated renal transplant recipients. Transplantation 1989; 48: 37-43.
43. de Grohen PC. Ciclosporine, low density lipoprotein, and cholesterol. Majo Clin Proc 1988; 63: 1012- 21.
44. Princen HM, Meijer P, Volthers BG, Vonk RG, Kuipers F. Cyclosporin A bloks bile acid synthesis ín cultured hepatocytes by specific inhibition of chenodeoxycholic acid synthesis. Biochem J 1991; 275 (part 2): 501-5.
45. Webb AT, Reaveley DA, O'Donnell M, O'Connor B, Seed M, Brown EA. Does cyclosporin increase lipoprotein (a) concentration in renal transplant recipients? The Lancet 1993; 341: 268-70.
46. Brown JH, Murphy BG, Douglas AF, et al. Influence of immunosoppressive therapy on lipoprotein (a) and other lipoproteins following renal transplantation. Nephron 1997; 75: 277-82.
47. Apanay DC, Neylan JF, Ragab MS, Sgoutas DS. Cyclosporine increases the oxidizability of low-density lipoproteins in renal transplant recipients. Transplantation 1994; 58: 663-9.
48. Van den Dorpel MA, Ghanem H, Rischen-Vos J, Man in't Veld AJ, Jansen H, Weimar W. Conversion from cyclosporine A to azathioprine treatment improves LDL oxidation in kidney transplant recipients. Kidney Int 1997; 51: 1608-12.
49. Swann SK. Role of lipids in chronic renal allograft rejection. In: Keane WF, Hörl WH, Kasiske BL, eds. Lipids and the kidney. Contrib Nephrol 1997; 120: 62-7.
50. Katznelson S. The effect of HMG-CoA reductase inhibitors on chronic allograft rejection. In: Keane WF, Horl WH, Kasiske BL, eds. Lipids and the kidney. Contrib Nephrol 1997; 120: 97-104.
51. Guijarro C, Massy ZA, Kasiske BL. Clinical correlation between renal allograft failure and hyperlipidemia. Kidney Int 1995; 48: S56-59.